Monoclonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after All.
Oliver C LomasTarek H MouhieddineSabrin TahriIrene M GhobrialPublished in: Cancers (2020)
Monoclonal Gammopathy of Undetermined Significance (MGUS) is considered to be a benign precursor condition that may progress to a lymphoproliferative disease or multiple myeloma. Most patients do not progress to an overt condition, but nevertheless, MGUS is associated with a shortened life expectancy and, in a minority of cases, a number of co-morbid conditions that include an increased fracture risk, renal impairment, peripheral neuropathy, secondary immunodeficiency, and cardiovascular disease. This review aims to consolidate current evidence for the significance of these co-morbidities before considering how best to approach these symptoms and signs, which are often encountered in primary care or within a number of specialties in secondary care.
Keyphrases
- multiple myeloma
- primary care
- cardiovascular disease
- end stage renal disease
- healthcare
- ejection fraction
- newly diagnosed
- chronic kidney disease
- palliative care
- prognostic factors
- bariatric surgery
- peritoneal dialysis
- patient reported outcomes
- quality improvement
- coronary artery disease
- physical activity
- cardiovascular events
- cardiovascular risk factors
- weight loss
- chronic pain
- general practice
- obese patients
- hip fracture